Navigation Links
Biopharmaceutical Alliances: Forging Partnerships That Work

CHAPEL HILL, N.C., April 30 /PRNewswire/ -- Intense global competition and today's networked economy have been the driving force behind companies adopting Strategic Alliances as the strategy of the next century. A strategic alliance must be a win-win situation for it to be sustainable and mutually beneficial.

How to build a win-win alliance? Best Practices, LLC's study on Forging Partnerships That Work is a roadmap to successful alliance formation. This study evaluates the significance of 10 factors for driving success in the establishment and evolution of alliance.

Best Practices, LLC conducted the study with two main objectives: 1) To identify the factors that companies with most successful alliances consider important and 2) to explain why those factors are considered most important. This study further explores the winning strategies and practices of nine pharmaceutical and biotech companies that have engaged in successful strategic alliances.

Among the questions answered in this study (Please read more in the downloadable excerpt):

-- What are the decisions that need to be made when beginning the

partnering process?

-- How can a partnership be used most strategically?

-- What do you ask for in a licensing/co-promotion deal?

Download a complimentary report summary of "Profitable Partnerships: Developing Excellence in Alliances" at .

If you have questions about this report or would like to speak to us about how our research can benefit your current initiatives in your company, please contact Cameron Tew, Manager of Research and Publishing at Best Practices, LLC at (919) 767-9246 or


Best Practices, LLC conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. Best Practices, LLC has been a leader in pharmaceutical research and consulting for nearly 15 years; our clients include 43 out of the top 50 pharmaceutical companies.

SOURCE Best Practices, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals Receives Nasdaq Notification
2. Ocular Biopharmaceutical Company Charlesson Announces $1.6MM in New Funding and Upcoming Presentations at The Association for Research in Vision and Ophthalmology
3. Ortho Biotech Oncology Research & Development Unites Johnson & Johnson Biopharmaceutical Oncology R&D Assets
4. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
5. R&D Spending by U.S. Biopharmaceutical Companies Reaches Record $58.8 Billion in 2007
6. XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals
7. Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors
8. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
9. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
10. PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
(Date:6/27/2016)... 2016  Global demand for enzymes is forecast ... to $7.2 billion.  This market includes enzymes used ... biofuel production, animal feed, and other markets) and ... Food and beverages will remain the largest market ... of products containing enzymes in developing regions.  These ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created 4Sight ... solutions to the healthcare market. The company's primary focus is on new product ... marketing strategies that are necessary to help companies efficiently bring their products to ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
Breaking Biology Technology:
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
Breaking Biology News(10 mins):